α1-Blockers and 5α-Reductase Inhibitors Are the Most Recommended Drugs in Treating Benign Prostatic Hyperplasia: An Evidence-Based Evaluation of Clinical Practice Guidelines

OBJECTIVE: To systematically evaluate the quality of clinical practice guidelines (CPG) for medically treating benign prostatic hyperplasia (BPH), and to compare the context of recommendations in order to provide references for clinical application. METHODS: We searched databases of National Guideli...

Descripción completa

Detalles Bibliográficos
Autores principales: Xu, Xiao-Feng, Liu, Guo-Xiong, Zhu, Cong, Qiao, Xi-Min, Yu, Shao-Fu, Deng, Tong, Jin, Ying-Hui
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2020
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7109311/
https://www.ncbi.nlm.nih.gov/pubmed/32269526
http://dx.doi.org/10.3389/fphar.2020.00311

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7109311/
https://www.ncbi.nlm.nih.gov/pubmed/32269526
http://dx.doi.org/10.3389/fphar.2020.00311

Ejemplares similares